Literature DB >> 8063382

Site-specific immunity to Leishmania major in SWR mice: the site of infection influences susceptibility and expression of the antileishmanial immune response.

G S Nabors1, J P Farrell.   

Abstract

Inbred strains of mice usually develop either of two divergent patterns of infection in response to Leishmania major. Resistant mice, which develop self-limiting infections, respond immunologically with the activation of gamma interferon-secreting Th1 helper T cells, while nonhealing infections in susceptible mice are characterized by the proliferation of interleukin-4-secreting Th2 cells. Development of these divergent responses is dependent primarily on the strain of mouse infected, although factors such as the infective dose, species, and strain of parasite can also influence the degree of resistance. In this study, we show that a single mouse strain, SWR, can develop totally divergent patterns of infection depending on the site of parasite inoculation. Both SWR mice and highly susceptible BALB/c mice developed progressive, ultimately fatal disease when inoculated in the dorsal skin over the base of the tail. However, SWR mice infected in the hind footpad developed far less severe infections, which were for the most part controlled, whereas BALB/c mice infected in this site developed severe, nonhealing lesions. Production of gamma interferon and interleukin-4 and measurement of immunoglobulin E levels in serum were used to assess the degree of Th1 and Th2 cell activation in infected mice. Cytokine profiles early in infection had characteristics of a mixed Th1-Th2 response and were similar in SWR mice infected at either site. These early cytokine responses were not predictive of the ultimate disease outcome, since lymph node cells from healing mice eventually produced higher levels of gamma interferon than did those from nonhealing mice, and healing mice had lower levels of immunoglobulin E in serum, suggesting a functional bias toward Th1 cell activity in these animals. The differential ability of SWR mice to heal infections at different cutaneous sites provides a new model for the study of resistance to cutaneous leishmaniasis. Unlike traditional models of infection in which resistant and susceptible strains of mice are compared, this model allows for the study of factors that contribute to healing and nonhealing infections in a genetically identical strain of mouse.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063382      PMCID: PMC303015          DOI: 10.1128/iai.62.9.3655-3662.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Leishmania braziliensis and Leishmania mexicana: experimental cutaneous infections in golden hamsters.

Authors:  H R Wilson; B S Dieckmann; G E Childs
Journal:  Exp Parasitol       Date:  1979-04       Impact factor: 2.011

2.  Experimental cutaneous leishmaniasis: disseminated leishmaniasis in genetically susceptible and resistant mice.

Authors:  P A Scott; J P Farrell
Journal:  Am J Trop Med Hyg       Date:  1982-03       Impact factor: 2.345

3.  Single gene control of resistance to cutaneous leishmaniasis in mice.

Authors:  L J DeTolla; P A Scott; J P Farrell
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

4.  Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse.

Authors:  P M Preston; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

5.  Natural killer cells are a source of interferon gamma that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice.

Authors:  T M Scharton; P Scott
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

6.  Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.

Authors:  M Belosevic; D S Finbloom; P H Van Der Meide; M V Slayter; C A Nacy
Journal:  J Immunol       Date:  1989-07-01       Impact factor: 5.422

7.  Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro.

Authors:  J D Berman; F A Neva
Journal:  Am J Trop Med Hyg       Date:  1981-03       Impact factor: 2.345

8.  Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell-dependent, interferon gamma-independent mechanism.

Authors:  M D Sadick; F P Heinzel; B J Holaday; R T Pu; R S Dawkins; R M Locksley
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

9.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Immunological regulation of experimental cutaneous leishmaniasis. IV. Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica.

Authors:  J G Howard; C Hale; F Y Liew
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  14 in total

1.  Effects of the nature of adjuvant and site of parenteral immunization on the serum and mucosal immune responses induced by a nasal boost with a vaccine alone.

Authors:  B Guy; S Fourage; C Hessler; V Sanchez; M J Millet
Journal:  Clin Diagn Lab Immunol       Date:  1998-09

2.  Site-dependent recruitment of inflammatory cells determines the effective dose of Leishmania major.

Authors:  Flavia L Ribeiro-Gomes; Eric Henrique Roma; Matheus B H Carneiro; Nicole A Doria; David L Sacks; Nathan C Peters
Journal:  Infect Immun       Date:  2014-04-14       Impact factor: 3.441

3.  Evaluation of s.c. route of immunization by homologous radio attenuated live vaccine in experimental murine model of visceral leishmaniasis.

Authors:  Sanchita Datta; Supriya Khanra; Anindita Chakraborty; Syamal Roy; Madhumita Manna
Journal:  J Parasit Dis       Date:  2014-09-20

4.  Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.

Authors:  Khaled S Tabbara; Nathan C Peters; Farhat Afrin; Susana Mendez; Sylvie Bertholet; Yasmine Belkaid; David L Sacks
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model.

Authors:  C G Beyrodt; A R Pinto; E Freymüller; C L Barbiéri
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  CD4(+) cells are indispensable for ulcer development in murine cutaneous leishmaniasis.

Authors:  M Terabe; T Kuramochi; M Ito; T Hatabu; C Sanjoba; K P Chang; T Onodera; Y Matsumoto
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

7.  Initial route of antigen administration alters the T-cell cytokine profile produced in response to the mouse pneumonitis biovar of Chlamydia trachomatis following genital infection.

Authors:  K A Kelly; E A Robinson; R G Rank
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

8.  The site of Leishmania major infection determines disease severity and immune responses.

Authors:  Tracey M Baldwin; Colleen Elso; Joan Curtis; Lynn Buckingham; Emanuela Handman
Journal:  Infect Immun       Date:  2003-12       Impact factor: 3.441

9.  Animal models for the analysis of immune responses to leishmaniasis.

Authors:  D L Sacks; P C Melby
Journal:  Curr Protoc Immunol       Date:  2001-05

10.  Gene Expression Architecture of Mouse Dorsal and Tail Skin Reveals Functional Differences in Inflammation and Cancer.

Authors:  David A Quigley; Eve Kandyba; Phillips Huang; Kyle D Halliwill; Jonas Sjölund; Facundo Pelorosso; Christine E Wong; Gillian L Hirst; Di Wu; Reyno Delrosario; Atul Kumar; Allan Balmain
Journal:  Cell Rep       Date:  2016-07-14       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.